Fasenra (Benralizumab)

Fasenra is an add-on maintenance treatment for patients aged 12 and older with severe Eosinophilic asthma. Fasenra is designed to target cells in your body called eosinophils, which can be a key cause of severe asthma.

Drug manufacturer information about Fasenra is available here.

Indication:

  • Add-on treatment for severe asthma 12 years and older with eosinophilic asthma

Injection Duration:

Frequency:

  • Loading Dose: Every 4-weeks for 3 injections

  • Maintenance Dose: Every 8-weeks